目的:探讨血清IL-32、IL-18、IL-1β及EpCAM在肝细胞癌的诊断、预后的临床价值.方法:前瞻性入组60例肝细胞癌患者和15例健康志愿者,在患者入院后给予相应治疗前采血,采用酶联免疫吸附法测定血清IL-32、IL-1β、IL-18及EpCAM水平.结果:HCC组患者血清IL-32、IL-18、EpCAM水平均显著高于对照组(P<0.05),HCC组与对照组的血清IL-1β水平无统计学差异(P>0.05);血清IL-32、IL-18水平与MELD评分正相关;EpCAM曲线下面积(AUC)为0.985,截断点为3.40,为诊断肝细胞癌最有价值的标志物;除了EpCAM,其它细胞因子与HCC患者的生存率无关(P>0.05).结论:虽然细胞因子可作为肝癌的诊断标志物,但其对肝细胞癌患者的预后没有参考价值;血清EpCAM可为肝细胞癌的诊断及患者的预后提供有效的参考价值.%Objective:To investigate interleukin (IL )-32 ,IL-1β,IL-18 and epithelial cell adhesion molecule (EpCAM ) in the diagnosis and assessment of prognosis of HCC .Methods:Sixty patients with HCC and 15 healthy volunteers were enrolled into this prospective study .Serum samples were obtained at the first admission before any treatment was given .Serum IL-32 ,IL-1β,IL-18 and EpCAM levels were determined by ELISA kits .Results :The mean serum level of IL-32 ,IL-18 and EpCAM in patients with HCC were significantly higher than in the control subjects (P<0 .05) .The mean IL-1βlevel in the HCC group was not different from that in the control group (P>0 .05) .IL-32 and IL-18 levels showed positive correlation with MELD scores .EpCAM with a cutoff of 3 .40 seems to be the most valuable marker for the diagnosis of HCC (AUC = 0 .985) .Cytokine levels except EpCAM did not correlate with survival (P>0 .05) .Conclusions :Although cytokines can be a diagnostic marker for HCC ,they did not have any significant prognostic value in patients with HCC .Only EpCAM may be used to determine the progno-sis of HCC ,thereby assisting with treatment management .
展开▼
